Resource Summary Report

Generated by PRECISE-TBI on Aug 31, 2026

SMARCB1/BAF47 (D8M1X) Rabbit mAb

RRID:AB_2800172
Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 91735, RRID:AB_2800172

Antibody Information

URL: http://antibodyregistry.org/AB_2800172

Proper Citation: Cell Signaling Technology Cat# 91735, RRID:AB_2800172

Target Antigen: SMARCB1

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IHC-P, ChIP, ChIP-seq

Antibody Name: SMARCB1/BAF47 (D8M1X) Rabbit mAb

Description: This monoclonal targets SMARCB1

Target Organism: h, m, r, mk

Clone ID: Clone D8M1X

Antibody ID: AB_2800172

Vendor: Cell Signaling Technology

Catalog Number: 91735

Record Creation Time: 20250820T000543+0000

Record Last Update: 20250820T072131+0000

Ratings and Alerts

No rating or validation information has been found for SMARCB1/BAF47 (D8M1X) Rabbit mAb.

No alerts have been found for SMARCB1/BAF47 (D8M1X) Rabbit mAb.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at PRECISE-TBI .

Jurmeister P, et al. (2026) Spatially resolved ex vivo drug response profiling in SMARCB1-deficient sinonasal carcinoma. EMBO molecular medicine, 18(6), 2360.

Neve B, et al. (2026) Long non-coding RNA UCA1 modulates SMARCA2-containing SWI/SNF chromatin remodeling complexes in human colorectal cancer. iScience, 29(1), 114283.

Ma X, et al. (2026) IAP-based biodegraders can convert necroptosis to apoptosis and eliminate cancer driving protein complexes. Cell chemical biology, 33(4), 553.

Zhao Z, et al. (2025) Sickle cell disease induces chromatin introversion and ferroptosis in CD8+ T cells to suppress anti-tumor immunity. Immunity, 58(6), 1484.

Sasaki M, et al. (2025) Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. Cancer research communications, 5(1), 24.

Nie H, et al. (2025) Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer. Cancer research, 85(18), 3471.

Deng Q, et al. (2024) SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions. Cancer cell.

Duplaquet L, et al. (2024) Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer. Cancer cell, 42(8), 1352.

Bolomsky A, et al. (2024) IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. Cancer cell, 42(7), 1185.

Cui L, et al. (2024) Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer. Cancer research.

Kotagiri S, et al. (2024) Enhancer reprogramming underlies therapeutic utility of a SMARCA2 degrader in SMARCA4 mutant cancer. Cell chemical biology, 31(12), 2069.

Liu W, et al. (2023) RNF138 inhibits late inflammatory gene transcription through degradation of SMARCC1 of the SWI/SNF complex. Cell reports, 42(2), 112097.

Zhou W, et al. (2023) Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis. Cancer cell, 41(4), 740.

Pintacuda G, et al. (2023) Protein interaction studies in human induced neurons indicate convergent biology underlying autism spectrum disorders. Cell genomics, 3(3), 100250.

Drosos Y, et al. (2022) NSD1 mediates antagonism between SWI/SNF and polycomb complexes and is required for transcriptional activation upon EZH2 inhibition. Molecular cell, 82(13), 2472.

Valencia AM, et al. (2019) Recurrent SMARCB1 Mutations Reveal a Nucleosome Acidic Patch Interaction Site That Potentiates mSWI/SNF Complex Chromatin Remodeling. Cell, 179(6), 1342.